Close Menu

NEW YORK — Avacta has signed an agreement to develop, manufacture, and distribute certain of its SARS-CoV-2 tests in collaboration with British diagnostics firm Mologic, the companies said on Monday.

Under the terms of the deal, Mologic will manage the CE marking of Avacta's AffiDx SARS-CoV-2 lateral flow rapid antigen test under its existing ISO13485 quality system. The CE mark will be transferred to Avacta once it is issued, which is expected to occur before the end of March.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.